Posted on 10/28/2021 8:24:09 PM PDT by SeekAndFind
The IC50 for the inhibition of viral replication were 0.3µM for M and 2.8µM for IV. Both drugs have good oral absorption, with M achieving peak plasma concentrations by 2 hours and IV by 5 hours.
The plasma half life were 7 hours for M and 81-91 hours for IV. M inhibits viral replication inducing viral mutagenesis in RdRp, causing viral error catastrophe and viral extinction.
IV affects viral cell entry, nuclear transport and inhibits replication via RdRp. IV has additional effect to suppress cytokine production through STAT-3 inhibition. M is a more potent antiviral drug and IV has a longer residence in the body.
Their effects on RdRp and cytokine inhibition are potentially complimentary for anti-COVID-19 activity.
Both IV and M should be compared in randomized controlled clinical trials, and the possibility of their combination for anti-SARS-CoV-2 antiviral actions, explored further.
(Excerpt) Read more at austinpublishinggroup.com ...
Ping for your interest
WATCH THIS VIDEO FOR A CLEAR EXPLANATION AND ANALYSIS OF THE PAPER BY DR. JOHN CAMPBELL:
Bottom line cheap and proven safe Ivermectin is significantly more effective in treating covid than the new, uber expensive, unproven, uncertified and, according to the paper, potentially dangerous Molnupiravir. The solution, of course, is a combined use of Ivermectin and Molnupiravir. Combining the two may be additive or even synergistic . Gee, wonder why they did not think of trying that with HCQ Z- pack and Ivermectin. Oh, they did and it works synergistically too. Of course, both are banned for use with covid
‘They’ don’t care about the blood of millions.
Pretty obvious what’s going on here: Monopolar (or whatever they call it) isn’t working, so they mix it with Ivermectin and then claim that the two together are effective.
Well, if that’s what it takes the wealthier countries to get a treatment started that Big Pharma will allow, then I guess it’s for the better, since we can print the money for it.
“Their effects on RdRp and cytokine inhibition are potentially complimentary for anti-COVID-19 activity.”
That’s good news.
Dr a George Fareed has been recommending IVM + HCQ for a long time.
“Bottom line cheap and proven safe Ivermectin is significantly more effective in treating covid than the new, uber expensive, unproven, uncertified and, according to the paper, potentially dangerous Molnupiravir.”
The research paper doesn’t say that at all. It actually says this, easily found in the “abstract” box:
“M is a more potent antiviral drug and IV has a longer residence in the body. Their effects on RdRp and cytokine inhibition are potentially complimentary for anti-COVID-19 activity”
Freepers need to read the actual source themselves instead of believing phony summations like you have concocted.
https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v9-id1149.pdf
...
p
Ping
The hanks
“ Molnupiravir active metabolite (NHC-5’ Triphosphate), acts as a competitive alternative substrate for the viral RNA dependent RNA polymerase (RdRp), causing viral mutagenesis or transition mutations, which leads to viral error catastrophe and extinction of replication [8].
There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells [9]. Ivermectin (Table 1) exhibits multifarious actions, ranging from binding to SARS-CoV-2 spike protein S, reducing cell entry via human ACE2 receptors, inhibition of the nuclear transport of viral proteins, which prevents interference with replication, to binding to RdRP, reducing the activity of the viral transcription -replication complex [10]. Ivermectin has additional effects on Signal Transduction Activation of Transcription (STAT-3) and inhibition of cytokine production and inflammation, which has not yet been shown for molnupiravir.”
https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v9-id1149.pdf
And the author of those paragraphs, as well as the rest of the paper, summed up his opinion in the abstract:
“M is a more potent antiviral drug and IV has a longer residence in the body. Their effects on RdRp and cytokine inhibition are potentially complimentary for anti-COVID-19 activity”
The WHOLE abstract
Abstract
“The pharmacology of anti-SARS-CoV-2 drugs, Molnupiravir (M) and repurposed Ivermectin (IV) were compared. The IC50 for the inhibition of viral replication were 0.3μM for M and 2.8μM for IV. Both drugs have good oral absorption, with M achieving peak plasma concentrations by 2 hours and IV by 5 hours. The plasma half life were 7 hours for M and 81-91 hours for IV. M inhibits viral replication inducing viral mutagenesis in RdRp, causing viral error catastrophe and viral extinction. IV affects viral cell entry, nuclear transport and inhibits replication via RdRp. IV has additional effect to suppress cytokine production through STAT-3 inhibition. M is a more potent antiviral drug and IV has a longer residence in the body. Their effects on RdRp and cytokine inhibition are potentially complimentary for anti-COVID-19 activity. Both IV and M should be compared in randomized controlled clinical trials, and the possibility of their combination for anti-SARS-CoV-2 antiviral actions, explored further.“
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.